Nature

Can patients with low-grade papillary bladder tumors be followed up with a cystoscopy interval of 6 months?

Over half of patients diagnosed with bladder cancer have low-grade, noninvasive papillary bladder tumors that are unlikely to become life-threatening; however, patients are often treated with ...
Nature

Patients with low-grade bladder tumors benefit from less-frequent, less-invasive follow-up

More than half of all patients diagnosed with bladder cancer have low-grade, noninvasive papillary tumors. Current treatment comprises initial transurethral resection (TUR), sometimes with immediate ...
Cure Today

UGN-102 May Improve Quality of Life Versus Surgery in Bladder Cancer

UGN-102 shows a 79.6% complete response rate in recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer. UGN-102 offers a non-surgical alternative, avoiding cystoscopy and anesthesia, ...
Finanznachrichten

Photocure: Clinical data presentations at the European Association of Urology (EAU) 2025 congress highlight the benefits of using Blue Light Cystoscopy in bladder cancer

This study investigated the short- and long-term oncology safety regarding recurrence and progression as well as perioperative pain after office-based Transurethral Laser Ablation (TULA) or ...
PR Newswire

Clinical data presentations at the European Association of Urology (EAU) 2025 congress highlight the benefits of using Blue Light Cystoscopy in bladder cancer

OSLO, Norway, March 24, 2025 /PRNewswire/ --Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces two abstract presentations at the 2025 European Association of Urology congress (EAU) in ...